Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Molecular Partners AGMLLCF 34 Net Cash per Share is $2.02 as of Mar. 2026, which is 8% above its 10-year median of 1.87. GuruFocus rates MLLCF with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 801 Biotechnology companies, Molecular Partners AG ranks better than 79.28% on this metric.
The historical rank and industry rank for Molecular Partners AG's Net Cash per Share or its related term are showing as below:
MLLCF'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.68 Med: 1.87 Max: 14.81
Current: 1.98
During the past 13 years, the highest Price-to-Net-Cash Ratio of Molecular Partners AG was 14.81. The lowest was 0.68. And the median was 1.87.
MLLCF's Price-to-Net-Cash is ranked better than 79.28% of 801
companies
in the Biotechnology industry
Industry Median: 5.05
vs MLLCF: 1.98
Molecular Partners AG (OTCPK:MLLCF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Molecular Partners AG Net Cash per Share Related Terms
Molecular Partners AG Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLLCF vs VRTX, REGN, RVMD: Net Cash per Share Comparison
For the Biotechnology subindustry, Molecular Partners AG's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Price-to-Net-Cash falls into.
Molecular Partners AG Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Molecular Partners AG's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG (MLLCF) has a Net Cash per Share of $2.02 as of Mar. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Molecular Partners AG and its competitors. This is near median its historical median of 1.87. Over the past decade, Molecular Partners AG's Net Cash per Share has ranged from 0.68 to 14.81. According to the industry distribution chart, Molecular Partners AG ranks #166 out of 801 companies in the Biotechnology industry, placing it in the top 20.7%.
Is Molecular Partners AG's Net Cash per Share too high?
Molecular Partners AG's current Net Cash per Share of $2.02 is near median its 10-year median of 1.87. Over the past 10 years, this metric has ranged from a low of 0.68 to a high of 14.81. The Biotechnology industry median Net Cash per Share is 5.05. Molecular Partners AG's value of $2.02 is 60% below this industry median. Based on the distribution chart, Molecular Partners AG ranks #166 out of 801 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Molecular Partners AG has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #166 out of 801 companies for Net Cash per Share. This places Molecular Partners AG in the top 21% of its industry — outperforming the majority of peers. The industry median Net Cash per Share is 5.05. Molecular Partners AG's value of $2.02 is 60% below this benchmark. Historically, Molecular Partners AG's own Net Cash per Share has ranged from 0.68 to 14.81 over the past decade. While the company's 10-year median is 1.87 vs. the industry median of 5.05, Molecular Partners AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.05, based on 801 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Molecular Partners AG's current Net Cash per Share of $2.02 is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Molecular Partners AG and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current Net Cash per Share is $2.02, which is near median its own 10-year median of 1.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Molecular Partners AG (MLLCF) has a current Net Cash per Share of $2.02. The current Net Cash per Share is $2.02, which is near median its 10-year median of 1.87 and 60% below the Biotechnology industry median of 5.05. Molecular Partners AG's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Net Cash per Share is $2.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
34GF Score
Get the complete analysis for MLLCF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
